Age-related treatment strategy and long-term outcome in acute myocardial infarction patients in the PCI era
BMC Cardiovascular Disorders, 04/26/2012Kala P et al.
In a consecutive AMI population, the older group (>65 years) was associated with a less pronounced impact of risk factors on long–term outcome. To ascertain the coronary anatomy by coronary angiography and proceed to PCI if suitable regardless of age is crucial in all patients, though the primary success rate of PCI in the older age is lower. Age, when viewed as a risk factor, was a dominant discriminating factor in all patients.
Retrospective multicenter analysis of 3814 consecutive acute myocardial infarction patients divided into two groups according to age (1800 patients [less than or equal to] 65 years and 2014 patients > 65 years).
Significantly more older patients had a history of diabetes mellitus and previous myocardial infarctions.
The older population had a significantly lower rate of coronary angiographies (1726; 95.9% vs. 1860; 92.4%, p < 0.0001), PCI (1541; 85.6% vs. 1505; 74.7%, p < 0.001), achievement of optimal final TIMI flow 3 (1434; 79.7% vs. 1343; 66.7%, p < 0.001) and higher rate of unsuccessful reperfusion with final TIMI flow 0–1 (46; 2.6% vs. 78; 3.9%, p = 0.022).
A total of 217 patients (5.7%) died during hospitalization, significantly more often in the older population (46; 2.6% vs. 171; 8.5%, p < 0.001).
The long–term mortality (data for 2847 patients from 2 centers) was higher in the older population as well (5 years survival: 86.1% vs. 59.8%).
Though not significantly different and in contrast with PCI, the presence of diabetes mellitus, previous MI, final TIMI flow and LAD, as the infarct–related artery, had relatively lower impact on the older patients.
Severe heart failure on admission (Killip III–IV) was associated with the worst prognosis in the whole group of patients, though its significance was higher in the youngers (HR 6.04 vs. 3.14, p = 0.051 for Killip III and 12.24 vs. 5.65, p = 0.030 for Killip IV).
Authors clearly demonstrated age as a strong discriminator for the whole population of AMI patients.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.